ReviewTzu chi medical journal
Prestin as a context-dependent biomarker of outer hair cell stress: Integrating preclinical and clinical evidence.
Review in Tzu chi medical journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The early detection of hearing loss remains a major clinical challenge. In many patients, once functional changes become evident on pure-tone audiometry, their recovery is limited. Outer hair cells (OHCs) are essential for cochlear amplification, and their injury is a common pathway in many forms of sensorineural hearing loss. However, reliable biomarkers that reflect hearing impairment in real-time are still lacking. Prestin, a motor protein located in the lateral membrane of OHCs, has been proposed as a potential marker of cochlear stress, but findings across studies vary, and its clinical significance remains uncertain. In this review, we re-examine current evidence to determine under which biological and clinical conditions serum prestin provides meaningful information. We examined data from models of cisplatin exposure, aminoglycoside ototoxicity, noise injury, cyclodextrin-related stress, and age-related hearing loss, along with available human studies. In acute injury models, circulating prestin often shows a transient increase during early OHC membrane damage, suggesting that it reflects active cellular stress. In contrast, chronic degenerative conditions and aging are associated with reduced cochlear prestin expression, which represents a gradual loss of OHC reserve rather than ongoing membrane injury. Differences in assay platforms, isoform detection, and sampling timing may contribute to inconsistent findings. Overall, prestin should not be viewed as a marker of hearing loss severity. Rather, it may indicate acute OHC membrane stress in specific contexts. When interpreted according to etiology and timing, it may help identify early cochlear stress and may support earlier monitoring or otoprotective intervention in selected settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.